Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2‐Drug Regimen Juluca, a Onepill‐Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms JUNGLE
- Sponsors ViiV Healthcare
- 29 Aug 2019 Planned End Date changed from 29 Jul 2022 to 1 Dec 2021.
- 29 Aug 2019 Planned primary completion date changed from 29 Jul 2022 to 1 Dec 2021.
- 29 Aug 2019 Status changed from recruiting to active, no longer recruiting.